US4450150A
(en)
|
1973-05-17 |
1984-05-22 |
Arthur D. Little, Inc. |
Biodegradable, implantable drug delivery depots, and method for preparing and using the same
|
US4232027A
(en)
|
1979-01-29 |
1980-11-04 |
E. R. Squibb & Sons, Inc. |
1,2-Dihydro-2-oxo-4-phenyl-3-quinolinecarbonitrile derivatives
|
GB2116183B
(en)
|
1982-03-03 |
1985-06-05 |
Genentech Inc |
Human antithrombin iii dna sequences therefore expression vehicles and cloning vectors containing such sequences and cell cultures transformed thereby a process for expressing human antithrombin iii and pharmaceutical compositions comprising it
|
WO1987005330A1
(en)
|
1986-03-07 |
1987-09-11 |
Michel Louis Eugene Bergh |
Method for enhancing glycoprotein stability
|
US4946778A
(en)
|
1987-09-21 |
1990-08-07 |
Genex Corporation |
Single polypeptide chain binding molecules
|
DE3853515T3
(de)
|
1987-05-21 |
2005-08-25 |
Micromet Ag |
Multifunktionelle proteine mit vorbestimmter zielsetzung.
|
US5223409A
(en)
|
1988-09-02 |
1993-06-29 |
Protein Engineering Corp. |
Directed evolution of novel binding proteins
|
GB8827305D0
(en)
|
1988-11-23 |
1988-12-29 |
British Bio Technology |
Compounds
|
JP2762522B2
(ja)
|
1989-03-06 |
1998-06-04 |
藤沢薬品工業株式会社 |
血管新生阻害剤
|
GB8912336D0
(en)
|
1989-05-30 |
1989-07-12 |
Smithkline Beckman Intercredit |
Compounds
|
US5112946A
(en)
|
1989-07-06 |
1992-05-12 |
Repligen Corporation |
Modified pf4 compositions and methods of use
|
ES2087997T3
(es)
|
1990-01-12 |
1996-08-01 |
Cell Genesys Inc |
Generacion de anticuerpos xenogenicos.
|
US6673986B1
(en)
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
GB9015198D0
(en)
|
1990-07-10 |
1990-08-29 |
Brien Caroline J O |
Binding substance
|
DK0546073T3
(da)
|
1990-08-29 |
1998-02-02 |
Genpharm Int |
Frembringelse og anvendelse af transgene, ikke-humane dyr, der er i stand til at danne heterologe antistoffer
|
US5545806A
(en)
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US6770274B1
(en)
|
1990-09-14 |
2004-08-03 |
The General Hospital Corporation |
Viral mutant HSV mediated destruction of neoplastic cells
|
PT98990A
(pt)
|
1990-09-19 |
1992-08-31 |
American Home Prod |
Processo para a preparacao de esteres de acidos carboxilicos de rapamicina
|
US5892112A
(en)
|
1990-11-21 |
1999-04-06 |
Glycomed Incorporated |
Process for preparing synthetic matrix metalloprotease inhibitors
|
ATE164395T1
(de)
|
1990-12-03 |
1998-04-15 |
Genentech Inc |
Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
|
US5780279A
(en)
|
1990-12-03 |
1998-07-14 |
Genentech, Inc. |
Method of selection of proteolytic cleavage sites by directed evolution and phagemid display
|
US5120842A
(en)
|
1991-04-01 |
1992-06-09 |
American Home Products Corporation |
Silyl ethers of rapamycin
|
US5100883A
(en)
|
1991-04-08 |
1992-03-31 |
American Home Products Corporation |
Fluorinated esters of rapamycin
|
US5118678A
(en)
|
1991-04-17 |
1992-06-02 |
American Home Products Corporation |
Carbamates of rapamycin
|
CA2066898A1
(en)
|
1991-04-29 |
1992-10-30 |
Chuan Shih |
Pharmaceutical compounds
|
JP3266311B2
(ja)
|
1991-05-02 |
2002-03-18 |
生化学工業株式会社 |
新規ポリペプチドおよびこれを用いる抗hiv剤
|
DK0584222T3
(da)
|
1991-05-10 |
1998-02-23 |
Rhone Poulenc Rorer Int |
Bis-mono- og bicycliske aryl- og heteroarylforbindelser, som inhiberer EGF- og/eller PDGF-receptor-tyrosinkinase
|
US5858657A
(en)
|
1992-05-15 |
1999-01-12 |
Medical Research Council |
Methods for producing members of specific binding pairs
|
DE69230142T2
(de)
|
1991-05-15 |
2000-03-09 |
Cambridge Antibody Technology Ltd. |
Verfahren zur herstellung von spezifischen bindungspaargliedern
|
US6225447B1
(en)
|
1991-05-15 |
2001-05-01 |
Cambridge Antibody Technology Ltd. |
Methods for producing members of specific binding pairs
|
US5118677A
(en)
|
1991-05-20 |
1992-06-02 |
American Home Products Corporation |
Amide esters of rapamycin
|
NZ243082A
(en)
|
1991-06-28 |
1995-02-24 |
Ici Plc |
4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
|
US5151413A
(en)
|
1991-11-06 |
1992-09-29 |
American Home Products Corporation |
Rapamycin acetals as immunosuppressant and antifungal agents
|
GB9125660D0
(en)
|
1991-12-03 |
1992-01-29 |
Smithkline Beecham Plc |
Novel compound
|
GB9300059D0
(en)
|
1992-01-20 |
1993-03-03 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9206422D0
(en)
|
1992-03-24 |
1992-05-06 |
Bolt Sarah L |
Antibody preparation
|
US7381803B1
(en)
|
1992-03-27 |
2008-06-03 |
Pdl Biopharma, Inc. |
Humanized antibodies against CD3
|
US5521184A
(en)
|
1992-04-03 |
1996-05-28 |
Ciba-Geigy Corporation |
Pyrimidine derivatives and processes for the preparation thereof
|
DE4221054A1
(de)
|
1992-06-30 |
1994-01-05 |
Herbst Bremer Goldschlaegerei |
Präparat zur prophylaktischen und therapeutischen Behandlung von Karies sowie Verfahren zum Herstellen desselben
|
ZA935112B
(en)
|
1992-07-17 |
1994-02-08 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
ZA935111B
(en)
|
1992-07-17 |
1994-02-04 |
Smithkline Beecham Corp |
Rapamycin derivatives
|
US5256790A
(en)
|
1992-08-13 |
1993-10-26 |
American Home Products Corporation |
27-hydroxyrapamycin and derivatives thereof
|
GB9221220D0
(en)
|
1992-10-09 |
1992-11-25 |
Sandoz Ag |
Organic componds
|
US5258389A
(en)
|
1992-11-09 |
1993-11-02 |
Merck & Co., Inc. |
O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
|
AU669960B2
(en)
|
1992-11-13 |
1996-06-27 |
Immunex Corporation |
Novel cytokine designated elk ligand
|
US5455258A
(en)
|
1993-01-06 |
1995-10-03 |
Ciba-Geigy Corporation |
Arylsulfonamido-substituted hydroxamic acids
|
US5855885A
(en)
|
1993-01-22 |
1999-01-05 |
Smith; Rodger |
Isolation and production of catalytic antibodies using phage technology
|
US5629327A
(en)
|
1993-03-01 |
1997-05-13 |
Childrens Hospital Medical Center Corp. |
Methods and compositions for inhibition of angiogenesis
|
US5516658A
(en)
|
1993-08-20 |
1996-05-14 |
Immunex Corporation |
DNA encoding cytokines that bind the cell surface receptor hek
|
CA2148931A1
(en)
|
1993-10-01 |
1995-04-13 |
Jurg Zimmermann |
Pyrimidineamine derivatives and processes for the preparation thereof
|
US5656643A
(en)
|
1993-11-08 |
1997-08-12 |
Rhone-Poulenc Rorer Pharmaceuticals Inc. |
Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
|
WO1995014023A1
(en)
|
1993-11-19 |
1995-05-26 |
Abbott Laboratories |
Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
|
BR9408323A
(pt)
|
1993-12-17 |
1997-08-19 |
Sandoz Ag |
Derivados de rapamicina
|
US5700823A
(en)
|
1994-01-07 |
1997-12-23 |
Sugen, Inc. |
Treatment of platelet derived growth factor related disorders such as cancers
|
IL112248A0
(en)
|
1994-01-25 |
1995-03-30 |
Warner Lambert Co |
Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
|
IL112249A
(en)
|
1994-01-25 |
2001-11-25 |
Warner Lambert Co |
Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
|
WO1995024190A2
(en)
|
1994-03-07 |
1995-09-14 |
Sugen, Inc. |
Receptor tyrosine kinase inhibitors for inhibiting cell proliferative disorders and compositions thereof
|
WO1995028484A1
(en)
|
1994-04-15 |
1995-10-26 |
Amgen Inc. |
Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
|
ES2109796T3
(es)
|
1994-05-03 |
1998-01-16 |
Ciba Geigy Ag |
Derivados de pirrolopirimidilo con efecto antiproliferante.
|
US5585096A
(en)
|
1994-06-23 |
1996-12-17 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
US5728379A
(en)
|
1994-06-23 |
1998-03-17 |
Georgetown University |
Tumor- or cell-specific herpes simplex virus replication
|
US6699468B1
(en)
|
1994-06-23 |
2004-03-02 |
Georgetown University |
Replication-competent herpes simplex virus mediates destruction of neoplastic cells
|
US6303769B1
(en)
|
1994-07-08 |
2001-10-16 |
Immunex Corporation |
Lerk-5 dna
|
US5919905A
(en)
|
1994-10-05 |
1999-07-06 |
Immunex Corporation |
Cytokine designated LERK-6
|
US6057124A
(en)
|
1995-01-27 |
2000-05-02 |
Amgen Inc. |
Nucleic acids encoding ligands for HEK4 receptors
|
US5863949A
(en)
|
1995-03-08 |
1999-01-26 |
Pfizer Inc |
Arylsulfonylamino hydroxamic acid derivatives
|
ES2332984T3
(es)
|
1995-03-30 |
2010-02-16 |
Pfizer Products Inc. |
Derivados de quinazolinas.
|
DE69609602T2
(de)
|
1995-04-03 |
2001-04-12 |
Novartis Ag, Basel |
Pyrazolderivate und verfahren zu deren herstellung
|
DK0821671T3
(da)
|
1995-04-20 |
2001-04-23 |
Pfizer |
Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
|
GB9508538D0
(en)
|
1995-04-27 |
1995-06-14 |
Zeneca Ltd |
Quinazoline derivatives
|
US5702892A
(en)
|
1995-05-09 |
1997-12-30 |
The United States Of America As Represented By The Department Of Health And Human Services |
Phage-display of immunoglobulin heavy chain libraries
|
US5747498A
(en)
|
1996-05-28 |
1998-05-05 |
Pfizer Inc. |
Alkynyl and azido-substituted 4-anilinoquinazolines
|
US5880141A
(en)
|
1995-06-07 |
1999-03-09 |
Sugen, Inc. |
Benzylidene-Z-indoline compounds for the treatment of disease
|
US5650415A
(en)
|
1995-06-07 |
1997-07-22 |
Sugen, Inc. |
Quinoline compounds
|
US6265150B1
(en)
|
1995-06-07 |
2001-07-24 |
Becton Dickinson & Company |
Phage antibodies
|
US5985890A
(en)
|
1995-06-09 |
1999-11-16 |
Novartis Ag |
Rapamycin derivatives
|
CZ1598A3
(cs)
|
1995-07-06 |
1998-04-15 |
Novartis Ag |
Pyrrolopyrimidiny a způsoby jejich přípravy
|
DE19534177A1
(de)
|
1995-09-15 |
1997-03-20 |
Merck Patent Gmbh |
Cyclische Adhäsionsinhibitoren
|
AR004010A1
(es)
|
1995-10-11 |
1998-09-30 |
Glaxo Group Ltd |
Compuestos heterociclicos
|
GB9523675D0
(en)
|
1995-11-20 |
1996-01-24 |
Celltech Therapeutics Ltd |
Chemical compounds
|
DE69624081T2
(de)
|
1995-12-20 |
2003-06-12 |
Agouron Pharmaceuticals, Inc. |
Matrix-metalloprotease Inhibitoren
|
AU1441497A
(en)
|
1996-01-23 |
1997-08-20 |
Novartis Ag |
Pyrrolopyrimidines and processes for their preparation
|
JP3406763B2
(ja)
|
1996-01-30 |
2003-05-12 |
東レ・ダウコーニング・シリコーン株式会社 |
シリコーンゴム組成物
|
GB9603095D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline derivatives
|
GB9603097D0
(en)
|
1996-02-14 |
1996-04-10 |
Zeneca Ltd |
Quinazoline compounds
|
DE19629652A1
(de)
|
1996-03-06 |
1998-01-29 |
Thomae Gmbh Dr K |
4-Amino-pyrimidin-Derivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
DE19608588A1
(de)
|
1996-03-06 |
1997-09-11 |
Thomae Gmbh Dr K |
Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
|
ATE244719T1
(de)
|
1996-03-15 |
2003-07-15 |
Novartis Pharma Gmbh |
N-7 heterocyclyl-pyrrolo( 2,3-d)pyrimidine und ihre verwendung
|
US5714352A
(en)
|
1996-03-20 |
1998-02-03 |
Xenotech Incorporated |
Directed switch-mediated DNA recombination
|
CZ295468B6
(cs)
|
1996-04-12 |
2005-08-17 |
Warner-Lambert Company |
Polycyklické sloučeniny
|
GB9607729D0
(en)
|
1996-04-13 |
1996-06-19 |
Zeneca Ltd |
Quinazoline derivatives
|
EP0907642B1
(en)
|
1996-06-24 |
2005-11-02 |
Pfizer Inc. |
Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
|
EP0937082A2
(en)
|
1996-07-12 |
1999-08-25 |
Ariad Pharmaceuticals, Inc. |
Materials and method for treating or preventing pathogenic fungal infection
|
EP0818442A3
(en)
|
1996-07-12 |
1998-12-30 |
Pfizer Inc. |
Cyclic sulphone derivatives as inhibitors of metalloproteinases and of the production of tumour necrosis factor
|
ID19609A
(id)
|
1996-07-13 |
1998-07-23 |
Glaxo Group Ltd |
Senyawa-senyawa heterosiklik
|
HRP970371A2
(en)
|
1996-07-13 |
1998-08-31 |
Kathryn Jane Smith |
Heterocyclic compounds
|
EP0912572B1
(en)
|
1996-07-13 |
2003-01-15 |
Glaxo Group Limited |
Bicyclic heteroaromatic compounds as protein tyrosine kinase inhibitors
|
YU1899A
(sh)
|
1996-07-18 |
2000-03-21 |
Pfizer Inc. |
Inhibitori matričnih metaloproteaza na bazi fosfinata
|
US5824318A
(en)
|
1996-07-24 |
1998-10-20 |
American Cyanamid Company |
Avirulent herpetic viruses useful as tumoricidal agents and vaccines
|
US6111090A
(en)
|
1996-08-16 |
2000-08-29 |
Schering Corporation |
Mammalian cell surface antigens; related reagents
|
ES2308787T3
(es)
|
1996-08-16 |
2008-12-01 |
Schering Corporation |
Antigenos de superficie de celular de mamiferos; reactivos relacionados.
|
EA199900139A1
(ru)
|
1996-08-23 |
1999-08-26 |
Пфайзер, Инк. |
Производные арилсульфониламиногидроксамовой кислоты
|
JP4242928B2
(ja)
|
1996-08-23 |
2009-03-25 |
ノバルティス アクチエンゲゼルシャフト |
置換ピロロピリミジンおよびその製造方法
|
ID18494A
(id)
|
1996-10-02 |
1998-04-16 |
Novartis Ag |
Turunan pirazola leburan dan proses pembuatannya
|
AU4779897A
(en)
|
1996-10-02 |
1998-04-24 |
Novartis Ag |
Fused pyrazole derivatives and processes for their preparation
|
US6251911B1
(en)
|
1996-10-02 |
2001-06-26 |
Novartis Ag |
Pyrimidine derivatives and processes for the preparation thereof
|
EP0837063A1
(en)
|
1996-10-17 |
1998-04-22 |
Pfizer Inc. |
4-Aminoquinazoline derivatives
|
GB9621757D0
(en)
|
1996-10-18 |
1996-12-11 |
Ciba Geigy Ag |
Phenyl-substituted bicyclic heterocyclyl derivatives and their use
|
CA2722378C
(en)
|
1996-12-03 |
2015-02-03 |
Amgen Fremont Inc. |
Human antibodies that bind tnf.alpha.
|
PT950059E
(pt)
|
1997-01-06 |
2004-10-29 |
Pfizer |
Derivados de sulfona ciclicos
|
AU721748B2
(en)
|
1997-02-03 |
2000-07-13 |
Pfizer Products Inc. |
Arylsulfonylamino hydroxamic acid derivatives
|
ATE391719T1
(de)
|
1997-02-05 |
2008-04-15 |
Warner Lambert Co |
Pyrido (2,3-d) pyrimidine und 4-amino-primidine als inhibitoren der zellulären proliferation
|
AU5493598A
(en)
|
1997-02-07 |
1998-08-26 |
Pfizer Inc. |
N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
|
EA002546B1
(ru)
|
1997-02-11 |
2002-06-27 |
Пфайзер Инк. |
Производные арилсульфонилгидроксамовой кислоты
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6057098A
(en)
|
1997-04-04 |
2000-05-02 |
Biosite Diagnostics, Inc. |
Polyvalent display libraries
|
US6150395A
(en)
|
1997-05-30 |
2000-11-21 |
The Regents Of The University Of California |
Indole-3-carbinol (I3C) derivatives and methods
|
AU8689298A
(en)
|
1997-08-05 |
1999-03-01 |
Sugen, Inc. |
Tricyclic quinoxaline derivatives as protein tyrosine kinase inhibitors
|
DK1003720T3
(da)
|
1997-08-08 |
2004-05-10 |
Pfizer Prod Inc |
Aryloxyarylsulfonylaminohydroxamsyrederivater
|
US6379674B1
(en)
|
1997-08-12 |
2002-04-30 |
Georgetown University |
Use of herpes vectors for tumor therapy
|
WO1999020758A1
(en)
|
1997-10-21 |
1999-04-29 |
Human Genome Sciences, Inc. |
Human tumor necrosis factor receptor-like proteins tr11, tr11sv1, and tr11sv2
|
GB9725782D0
(en)
|
1997-12-05 |
1998-02-04 |
Pfizer Ltd |
Therapeutic agents
|
GB9800575D0
(en)
|
1998-01-12 |
1998-03-11 |
Glaxo Group Ltd |
Heterocyclic compounds
|
RS49779B
(sr)
|
1998-01-12 |
2008-06-05 |
Glaxo Group Limited, |
Biciklična heteroaromatična jedinjenja kao inhibitori protein tirozin kinaze
|
GB9801690D0
(en)
|
1998-01-27 |
1998-03-25 |
Pfizer Ltd |
Therapeutic agents
|
AU2591599A
(en)
|
1998-02-09 |
1999-08-23 |
Genentech Inc. |
Novel tumor necrosis factor receptor homolog and nucleic acids encoding the same
|
KR20010040819A
(ko)
|
1998-02-10 |
2001-05-15 |
가마꾸라 아끼오 |
제어방출형 제제
|
CA2322311C
(en)
|
1998-03-04 |
2009-10-13 |
Bristol-Myers Squibb Company |
Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
|
PA8469401A1
(es)
|
1998-04-10 |
2000-05-24 |
Pfizer Prod Inc |
Derivados biciclicos del acido hidroxamico
|
PA8469501A1
(es)
|
1998-04-10 |
2000-09-29 |
Pfizer Prod Inc |
Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
|
WO1999054440A1
(en)
|
1998-04-21 |
1999-10-28 |
Micromet Gesellschaft Für Biomedizinische Forschung Mbh |
CD19xCD3 SPECIFIC POLYPEPTIDES AND USES THEREOF
|
CO5031249A1
(es)
|
1998-05-29 |
2001-04-27 |
Sugen Inc |
Pirrol substituido-2-indolinonas inhibidoras de proteinci-nasas
|
UA60365C2
(uk)
|
1998-06-04 |
2003-10-15 |
Пфайзер Продактс Інк. |
Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
|
AU747427B2
(en)
|
1998-07-10 |
2002-05-16 |
Merck & Co., Inc. |
Novel angiogenesis inhibitors
|
GB9815909D0
(en)
|
1998-07-21 |
1998-09-16 |
Btg Int Ltd |
Antibody preparation
|
JP2002523459A
(ja)
|
1998-08-31 |
2002-07-30 |
メルク エンド カムパニー インコーポレーテッド |
新規血管形成阻害剤
|
DE69915004T2
(de)
|
1998-11-05 |
2004-09-09 |
Pfizer Products Inc., Groton |
5-Oxo-pyrrolidine-2-Carbonsäure-Hydroxamidderivate
|
GB2344287A
(en)
|
1998-12-03 |
2000-06-07 |
Ferring Bv |
Controlled release pharmaceutical formulation
|
CA2356937A1
(en)
|
1998-12-31 |
2000-07-13 |
Richard J. Whitley |
Recombinant herpes simplex virus useful for treating neoplastic disease
|
IL144144A0
(en)
|
1999-01-13 |
2002-05-23 |
Bayer Ag |
Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
WO2000054795A1
(en)
|
1999-03-15 |
2000-09-21 |
The Trustees Of The University Of Pennsylvania |
Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
|
ATE329596T1
(de)
|
1999-03-30 |
2006-07-15 |
Novartis Pharma Gmbh |
Phthalazinderivate zur behandlung von entzündlicher erkrankungen
|
GB9912961D0
(en)
|
1999-06-03 |
1999-08-04 |
Pfizer Ltd |
Metalloprotease inhibitors
|
US6413932B1
(en)
|
1999-06-07 |
2002-07-02 |
Immunex Corporation |
Tek antagonists comprising soluble tek extracellular binding domain
|
US6521424B2
(en)
|
1999-06-07 |
2003-02-18 |
Immunex Corporation |
Recombinant expression of Tek antagonists
|
US6764675B1
(en)
|
1999-06-08 |
2004-07-20 |
The Uab Research Foundation |
Herpes simplex virus expressing foreign genes and method for treating cancers therewith
|
US6833268B1
(en)
|
1999-06-10 |
2004-12-21 |
Abgenix, Inc. |
Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
|
PT1196186E
(pt)
|
1999-07-12 |
2008-02-14 |
Genentech Inc |
Promoção ou inibição da angiogénese e da cardiovascularização com homólogos de ligandos/receptores do factor de necrose tumoral.
|
ES2219388T3
(es)
|
1999-08-24 |
2004-12-01 |
Ariad Gene Therapeutics, Inc. |
28-epi-rapalogos.
|
ES2265998T3
(es)
|
1999-11-05 |
2007-03-01 |
Astrazeneca Ab |
Derivados de quizazolina como inhibidores de vegf.
|
DK1233943T3
(da)
|
1999-11-24 |
2011-08-15 |
Sugen Inc |
Ioniserbare indolinon derivater og anvendelse deraf som PTK ligander
|
US6515004B1
(en)
|
1999-12-15 |
2003-02-04 |
Bristol-Myers Squibb Company |
N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases
|
US6727225B2
(en)
|
1999-12-20 |
2004-04-27 |
Immunex Corporation |
TWEAK receptor
|
KR100768408B1
(ko)
|
2000-01-21 |
2007-10-18 |
바이오벡스 리미티드 |
헤르페스 바이러스 주
|
CA2398136A1
(en)
|
2000-02-08 |
2001-08-16 |
The Penn State Research Foundation |
Immunotherapy using interleukin 13 receptor subunit alpha 2
|
JP2003523768A
(ja)
|
2000-02-25 |
2003-08-12 |
イミュネックス・コーポレーション |
インテグリンアンタゴニスト
|
DZ3401A1
(fr)
|
2000-07-19 |
2002-01-24 |
Warner Lambert Co |
Esters oxygenes d'acides 4-iodophenylamino benzhydroxamiques
|
US6630500B2
(en)
|
2000-08-25 |
2003-10-07 |
Cephalon, Inc. |
Selected fused pyrrolocarbazoles
|
ATE430742T1
(de)
|
2000-12-21 |
2009-05-15 |
Smithkline Beecham Corp |
Pyrimidinamine als angiogenesemodulatoren
|
US7105682B2
(en)
|
2001-01-12 |
2006-09-12 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US7102009B2
(en)
|
2001-01-12 |
2006-09-05 |
Amgen Inc. |
Substituted amine derivatives and methods of use
|
US20020147198A1
(en)
|
2001-01-12 |
2002-10-10 |
Guoqing Chen |
Substituted arylamine derivatives and methods of use
|
US6878714B2
(en)
|
2001-01-12 |
2005-04-12 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
US6995162B2
(en)
|
2001-01-12 |
2006-02-07 |
Amgen Inc. |
Substituted alkylamine derivatives and methods of use
|
CA2441663C
(en)
|
2001-03-27 |
2013-01-22 |
Medigene, Inc. |
Viral vectors and their use in therapeutic methods
|
AR036993A1
(es)
|
2001-04-02 |
2004-10-20 |
Wyeth Corp |
Uso de agentes que modulan la interaccion entre pd-1 y sus ligandos en la submodulacion de respuestas inmunologicas
|
EP1461423B1
(en)
|
2001-12-03 |
2008-05-14 |
Amgen Fremont Inc. |
Antibody categorization based on binding characteristics
|
JP2002233610A
(ja)
|
2002-02-18 |
2002-08-20 |
Olympia:Kk |
スロットマシン
|
US7307088B2
(en)
|
2002-07-09 |
2007-12-11 |
Amgen Inc. |
Substituted anthranilic amide derivatives and methods of use
|
TWI329112B
(en)
|
2002-07-19 |
2010-08-21 |
Bristol Myers Squibb Co |
Novel inhibitors of kinases
|
US7917208B2
(en)
|
2002-10-04 |
2011-03-29 |
Microchips, Inc. |
Medical device for controlled drug delivery and cardiac monitoring and/or stimulation
|
CN1513993A
(zh)
|
2002-12-31 |
2004-07-21 |
北京博泰迪生物工程科技开发有限公司 |
中国人基因组cDNA文库白细胞介素21的编码基因序列及其蛋白质的氨基酸序列
|
US20050009849A1
(en)
|
2003-01-03 |
2005-01-13 |
Veach Darren R. |
Pyridopyrimidine kinase inhibitors
|
WO2004107618A2
(en)
|
2003-05-23 |
2004-12-09 |
Wyeth |
Gitr ligand and gitr ligand-related molecules and antibodies and uses thereof
|
US7635472B2
(en)
|
2003-05-31 |
2009-12-22 |
Micromet Ag |
Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
|
PT1646634E
(pt)
|
2003-07-08 |
2009-02-16 |
Novartis Ag |
Utilização de rapamicina e derivados de rapamicina para o tratamento de perda óssea
|
WO2005016252A2
(en)
|
2003-07-11 |
2005-02-24 |
Ariad Gene Therapeutics, Inc. |
Phosphorus-containing macrocycles
|
WO2005007190A1
(en)
|
2003-07-11 |
2005-01-27 |
Schering Corporation |
Agonists or antagonists of the clucocorticoid-induced tumour necrosis factor receptor (gitr) or its ligand for the treatment of immune disorders, infections and cancer
|
AR045134A1
(es)
|
2003-07-29 |
2005-10-19 |
Smithkline Beecham Plc |
Compuesto de 1h - imidazo [4,5-c] piridin-ilo, composicion farmaceutica que lo comprende, proceso para prepararla, su uso para preparar dicha composicion farmaceutica, combinacion farmaceutica, uso de la combinacion farmaceutica para la preparacion de un medicamento, procedimientos para preparar dic
|
WO2005021546A1
(en)
|
2003-08-22 |
2005-03-10 |
Avanir Pharmaceuticals |
Substituted naphthyridine derivatives as inhibitors of macrophage migration inhibitory factor and their use in the treatment of human diseases
|
AU2004283850C1
(en)
|
2003-10-16 |
2011-11-03 |
Amgen Research (Munich) Gmbh |
Multispecific deimmunized CD3-binders
|
JP2007518399A
(ja)
|
2003-12-02 |
2007-07-12 |
ジェンザイム コーポレイション |
肺癌を診断および治療する組成物並びに方法
|
GB0409799D0
(en)
|
2004-04-30 |
2004-06-09 |
Isis Innovation |
Method of generating improved immune response
|
AU2005250499B2
(en)
|
2004-06-03 |
2011-12-08 |
Novimmune S.A. |
Anti-CD3 antibodies and methods of use thereof
|
WO2006083289A2
(en)
|
2004-06-04 |
2006-08-10 |
Duke University |
Methods and compositions for enhancement of immunity by in vivo depletion of immunosuppressive cell activity
|
US7731952B2
(en)
|
2004-06-24 |
2010-06-08 |
New York University |
Avirulent oncolytic herpes simplex virus strains engineered to counter the innate host response
|
EA013678B1
(ru)
|
2004-08-26 |
2010-06-30 |
Пфайзер Инк. |
Энантиомерно чистые аминогетероарильные соединения в качестве ингибиторов протеинкиназы
|
PE20060608A1
(es)
|
2004-10-13 |
2006-08-22 |
Wyeth Corp |
Analogos de 17-hidroxiwortmanina como inhibidores de pi3k
|
WO2006044860A2
(en)
|
2004-10-18 |
2006-04-27 |
Amgen, Inc. |
Thiadiazole compounds and methods of use
|
WO2006099268A2
(en)
|
2005-03-14 |
2006-09-21 |
Merck & Co., Inc. |
Cgrp receptor antagonists
|
DK2343320T3
(da)
|
2005-03-25 |
2018-01-29 |
Gitr Inc |
Anti-gitr-antistoffer og anvendelser deraf
|
EP3530736A3
(en)
|
2005-05-09 |
2019-11-06 |
ONO Pharmaceutical Co., Ltd. |
Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
CN101267824A
(zh)
|
2005-09-20 |
2008-09-17 |
辉瑞产品公司 |
使用酪氨酸激酶抑制剂的治疗剂型和方法
|
BRPI0706621A2
(pt)
|
2006-01-18 |
2011-04-05 |
Amgen Inc |
composto, composição farmacêutica, métodos para tratar um distúrbio mediado por quinase em um mamìfero e para tratar um distúrbio relacionado com a proliferação em um mamìfero, e , uso do composto
|
US20110212086A1
(en)
|
2006-01-19 |
2011-09-01 |
Genzyme Corporation |
GITR Antibodies For The Treatment of Cancer
|
TW200745163A
(en)
|
2006-02-17 |
2007-12-16 |
Syntonix Pharmaceuticals Inc |
Peptides that block the binding of IgG to FcRn
|
NZ578162A
(en)
|
2006-12-07 |
2011-12-22 |
Genentech Inc |
Phosphoinositide 3-kinase inhibitor compounds and methods of use
|
CN101230335B
(zh)
|
2007-01-22 |
2010-08-11 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
CN101230334B
(zh)
|
2007-01-22 |
2011-06-01 |
北京奥源和力生物技术有限公司 |
单纯疱疹病毒和重组病毒及宿主细胞及其药物组合物
|
PL2139882T3
(pl)
|
2007-03-23 |
2014-05-30 |
Amgen Inc |
3-podstawione pochodne chinoliny lub chinoksaliny i ich zastosowanie jako inhibitorów 3-kinazy fosfatydyloinozytolu (pi3k)
|
MX2009009968A
(es)
|
2007-03-23 |
2009-10-08 |
Amgen Inc |
Compuestos heterociclicos y sus usos.
|
US7919498B2
(en)
|
2007-03-23 |
2011-04-05 |
Amgen Inc. |
Substituted pyrazolo[3,4-d]pyrimidines as PI3K inhibitors
|
TR201816277T4
(tr)
|
2007-04-03 |
2018-11-21 |
Amgen Res Munich Gmbh |
Çapraz-tür-spesifik bağlama alanı.
|
RS58217B1
(sr)
|
2007-04-03 |
2019-03-29 |
Amgen Res Munich Gmbh |
Interspecijski specifičan vezujući domen
|
CA2683698C
(en)
|
2007-04-19 |
2013-09-10 |
Hyun Hee Kwak |
A biodegradable microsphere composition suitable for the controlled release of glucose controlling peptide and formulation thereof
|
EP2170887A2
(en)
|
2007-06-07 |
2010-04-07 |
Amgen Inc. |
Heterocyclic compounds as raf kinase modulators
|
JP5932217B2
(ja)
|
2007-07-12 |
2016-06-08 |
ジーアイティーアール, インコーポレイテッド |
Gitr結合分子を使用する併用療法
|
WO2009011871A2
(en)
|
2007-07-17 |
2009-01-22 |
Amgen Inc. |
Thiadiazole modulators of pkb
|
JP2010533715A
(ja)
|
2007-07-17 |
2010-10-28 |
アムジエン・インコーポレーテツド |
複素環系pkb調節剤
|
WO2009017822A2
(en)
|
2007-08-02 |
2009-02-05 |
Amgen Inc. |
Pi3 kinase modulators and methods of use
|
AU2008298948B2
(en)
|
2007-09-12 |
2014-09-04 |
F. Hoffmann-La Roche Ag |
Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents, and methods of use
|
ES2439705T3
(es)
|
2007-10-25 |
2014-01-24 |
Genentech, Inc. |
Proceso para la preparación de compuestos de tienopirimidina
|
JP5520831B2
(ja)
|
2007-12-19 |
2014-06-11 |
アムジエン・インコーポレーテツド |
Pi3キナーゼの阻害薬
|
EA201001030A1
(ru)
|
2007-12-19 |
2011-02-28 |
Амген Инк. |
Конденсированные соединения пиридина, пиримидина и триазина в качестве ингибиторов клеточного цикла
|
EP2262837A4
(en)
|
2008-03-12 |
2011-04-06 |
Merck Sharp & Dohme |
PD-1 BINDING PROTEINS
|
US8389533B2
(en)
|
2008-04-07 |
2013-03-05 |
Amgen Inc. |
Gem-disubstituted and spirocyclic amino pyridines/pyrimidines as cell cycle inhibitors
|
WO2009127691A1
(en)
|
2008-04-17 |
2009-10-22 |
Ablynx N.V. |
Peptides capable of binding to serum proteins and compounds, constructs and polypeptides comprising the same
|
CA2725014C
(en)
|
2008-05-30 |
2014-06-17 |
Amgen Inc. |
Inhibitors of pi3 kinase
|
NZ590667A
(en)
|
2008-07-02 |
2013-01-25 |
Emergent Product Dev Seattle |
Tgf-b antagonist multi-target binding proteins
|
WO2010030002A1
(ja)
|
2008-09-12 |
2010-03-18 |
国立大学法人三重大学 |
外来性gitrリガンド発現細胞
|
ME02485B
(me)
|
2008-10-01 |
2017-02-20 |
Amgen Res Munich Gmbh |
Bispecifično jednolančano protutijelo psmaxcd3 s međuvrsnom specifičnošću
|
EP2387570A1
(en)
|
2009-01-15 |
2011-11-23 |
Amgen, Inc |
Fluoroisoquinoline substituted thiazole compounds and methods of use
|
CA2752527C
(en)
|
2009-02-18 |
2014-09-23 |
Amgen Inc. |
Indole/benzimidazole compounds as mtor kinase inhibitors
|
EP2406282A1
(en)
|
2009-03-11 |
2012-01-18 |
Novo Nordisk A/S |
Interleukin-21 variants having antagonistic binding to the il-21 receptor
|
CA2755285C
(en)
|
2009-03-20 |
2014-02-11 |
Yunxin Y. Bo |
Inhibitors of pi3 kinase
|
UY32582A
(es)
|
2009-04-28 |
2010-11-30 |
Amgen Inc |
Inhibidores de fosfoinositida 3 cinasa y/u objetivo mamífero
|
US20120190666A1
(en)
|
2009-05-13 |
2012-07-26 |
Amgen Inc. |
Heteroaryl Compounds as PIKK Inhibitors
|
CA2765823A1
(en)
|
2009-06-25 |
2010-12-29 |
Amgen Inc. |
Tricyclic heterocyclic compounds as mediators of p13k activity
|
AR077267A1
(es)
|
2009-06-25 |
2011-08-17 |
Amgen Inc |
Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
|
MX2011013901A
(es)
|
2009-06-25 |
2012-05-08 |
Amgen Inc |
Derivados de 4h-pirido [1,2-a] pirimidin-4-ona como inhibidores de pi3k.
|
JP2012531436A
(ja)
|
2009-06-25 |
2012-12-10 |
アムジエン・インコーポレーテツド |
複素環式化合物およびそれらのpi3k活性阻害剤としての使用
|
CN102471378B
(zh)
|
2009-06-26 |
2014-04-02 |
瑞泽恩制药公司 |
容易地分离的具有天然免疫球蛋白形式的双特异性抗体
|
CN102574924A
(zh)
|
2009-09-03 |
2012-07-11 |
先灵公司 |
抗-gitr抗体
|
WO2011031842A1
(en)
|
2009-09-11 |
2011-03-17 |
Amgen Inc. |
N-4 ( - ( ( 3- ( 2 -amino-4 pyrimidinyl) -2 -pyridinyl) oxy) phenyl) -4- (4-methyl-2-thienyl) -1-phthalazinamine for use in the treatment of antimitotic agent resistant cancer
|
GB0919054D0
(en)
|
2009-10-30 |
2009-12-16 |
Isis Innovation |
Treatment of obesity
|
CA2776241A1
(en)
|
2009-10-30 |
2011-05-05 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
BR112012016135A2
(pt)
|
2009-12-29 |
2017-03-07 |
Emergent Product Dev Seattle |
proteínas de ligação de heterodímero e seus usos
|
WO2012059486A1
(en)
|
2010-11-01 |
2012-05-10 |
Novozymes Biopharma Dk A/S |
Albumin variants
|
WO2012125495A2
(en)
|
2011-03-11 |
2012-09-20 |
Amgen Inc. |
Method of correlated mutational analysis to improve therapeutic antibodies
|
EP3354640A3
(en)
|
2011-04-13 |
2018-10-31 |
Innovimmune Biotherapeutics, Inc. |
Mif inhibitors and their uses
|
GB2491006A
(en)
|
2011-05-05 |
2012-11-21 |
Novozymes Biopharma Uk Ltd |
Albumin variants
|
US20130028882A1
(en)
|
2011-07-07 |
2013-01-31 |
Humanitas Technology, LLC |
Antiviral compositions and methods of their use
|
LT2753355T
(lt)
|
2011-09-08 |
2019-01-25 |
New York University |
Onkolitinis herpes simplex virusas ir jo terapinis panaudojimas
|
WO2013039954A1
(en)
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
TWI679212B
(zh)
|
2011-11-15 |
2019-12-11 |
美商安進股份有限公司 |
針對bcma之e3以及cd3的結合分子
|
EP2780364A2
(en)
|
2011-11-18 |
2014-09-24 |
Eleven Biotherapeutics, Inc. |
Proteins with improved half-life and other properties
|
US9447160B2
(en)
|
2012-01-19 |
2016-09-20 |
University Of Miami |
Compositions, methods and kits for treatment of cancer and autoimmune diseases
|
ES2664328T3
(es)
|
2012-03-16 |
2018-04-19 |
Albumedix A/S |
Variantes de albúmina
|
WO2013155223A1
(en)
|
2012-04-10 |
2013-10-17 |
The Regents Of The University Of California |
Compositions and methods for treating cancer
|
EP2847219A1
(en)
|
2012-05-07 |
2015-03-18 |
Amgen Inc. |
Anti-erythropoietin antibodies
|
WO2013169693A1
(en)
|
2012-05-09 |
2013-11-14 |
Bristol-Myers Squibb Company |
Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody
|
US9725462B2
(en)
|
2012-08-07 |
2017-08-08 |
Merck Patent Gmbh |
Pyridopyrimidine derivatives as protein kinase inhibitors
|
GB2512156A
(en)
|
2012-11-08 |
2014-09-24 |
Novozymes Biopharma Dk As |
Albumin variants
|
WO2014143659A1
(en)
|
2013-03-15 |
2014-09-18 |
Araxes Pharma Llc |
Irreversible covalent inhibitors of the gtpase k-ras g12c
|
AU2014239542A1
(en)
|
2013-03-15 |
2015-10-01 |
Araxes Pharma Llc |
Covalent inhibitors of KRas G12C
|
UY35464A
(es)
|
2013-03-15 |
2014-10-31 |
Araxes Pharma Llc |
Inhibidores covalentes de kras g12c.
|
WO2015000585A1
(en)
|
2013-07-02 |
2015-01-08 |
Walter Sebald |
Muteins of cytokines of the gamma-chain receptor family conjugated to a non-protein group
|
GB201312059D0
(en)
|
2013-07-05 |
2013-08-21 |
Univ Leuven Kath |
Novel GAK modulators
|
CN106488910B
(zh)
*
|
2013-10-10 |
2020-07-31 |
亚瑞克西斯制药公司 |
Kras g12c的抑制剂
|
TWI659021B
(zh)
|
2013-10-10 |
2019-05-11 |
亞瑞克西斯製藥公司 |
Kras g12c之抑制劑
|
GB201320729D0
(en)
|
2013-11-25 |
2014-01-08 |
Cancer Rec Tech Ltd |
Therapeutic compounds and their use
|
BR112016016421B1
(pt)
|
2014-01-20 |
2022-10-18 |
Cleave Biosciences, Inc |
Composto de pirimidina fundida, composição farmacêutica e respectivos uso
|
US20170166620A1
(en)
|
2014-02-19 |
2017-06-15 |
Merck Patent Gmbh |
Cancer-targeted il-12 immunotherapy
|
WO2016035008A1
(en)
|
2014-09-04 |
2016-03-10 |
Lupin Limited |
Pyridopyrimidine derivatives as mek inhibitors
|
JO3556B1
(ar)
|
2014-09-18 |
2020-07-05 |
Araxes Pharma Llc |
علاجات مدمجة لمعالجة السرطان
|
WO2016049568A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Methods and compositions for inhibition of ras
|
WO2016049565A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Compositions and methods for inhibition of ras
|
WO2016049524A1
(en)
|
2014-09-25 |
2016-03-31 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
KR20180005178A
(ko)
|
2015-04-10 |
2018-01-15 |
아락세스 파마 엘엘씨 |
치환된 퀴나졸린 화합물 및 이의 사용방법
|
WO2016168540A1
(en)
|
2015-04-15 |
2016-10-20 |
Araxes Pharma Llc |
Fused-tricyclic inhibitors of kras and methods of use thereof
|
EP3325447A1
(en)
|
2015-07-22 |
2018-05-30 |
Araxes Pharma LLC |
Substituted quinazoline compounds and their use as inhibitors of g12c mutant kras, hras and/or nras proteins
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究(慕尼黑)公司 |
Flt3及cd3抗體構築體
|
TWI793062B
(zh)
|
2015-07-31 |
2023-02-21 |
德商安美基研究(慕尼黑)公司 |
Dll3及cd3抗體構築體
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究(慕尼黑)公司 |
Egfrviii及cd3抗體構築體
|
US10875842B2
(en)
|
2015-09-28 |
2020-12-29 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
WO2017058915A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
US10730867B2
(en)
|
2015-09-28 |
2020-08-04 |
Araxes Pharma Llc |
Inhibitors of KRAS G12C mutant proteins
|
EP3356351A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
EP3356353A1
(en)
|
2015-09-28 |
2018-08-08 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
EP3356359B1
(en)
|
2015-09-28 |
2021-10-20 |
Araxes Pharma LLC |
Inhibitors of kras g12c mutant proteins
|
WO2017058902A1
(en)
|
2015-09-28 |
2017-04-06 |
Araxes Pharma Llc |
Inhibitors of kras g12c mutant proteins
|
CA3005089A1
(en)
*
|
2015-11-16 |
2017-05-26 |
Araxes Pharma Llc |
2-substituted quinazoline compounds comprising a substituted heterocyclic group and methods of use thereof
|
US9988357B2
(en)
|
2015-12-09 |
2018-06-05 |
Araxes Pharma Llc |
Methods for preparation of quinazoline derivatives
|
RS64588B1
(sr)
|
2015-12-22 |
2023-10-31 |
Regeneron Pharma |
Kombinacija anti-pd-1 antitela i bispecifičnih anti-cd20/anti-cd3 antitela za lečenje kancera
|
ES2943150T3
(es)
|
2016-01-08 |
2023-06-09 |
Replimune Ltd |
Cepa de virus oncolítico
|
EA039859B1
(ru)
|
2016-02-03 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
UY37105A
(es)
|
2016-02-03 |
2017-09-29 |
Amgen Res (Munich) Gmbh |
Constructos de anticuerpo biespecíficos para psma y cd3 que se ligan a células t
|
CN116063544A
(zh)
|
2016-02-03 |
2023-05-05 |
安进研发(慕尼黑)股份有限公司 |
Bcma和cd3双特异性t细胞接合抗体构建体
|
WO2017172979A1
(en)
|
2016-03-30 |
2017-10-05 |
Araxes Pharma Llc |
Substituted quinazoline compounds and methods of use
|
MY201207A
(en)
|
2016-04-01 |
2024-02-09 |
Amgen Inc |
Chimeric receptors to flt3 and methods of use thereof
|
EP3380621A4
(en)
|
2016-04-22 |
2019-05-08 |
Immvira Co., Limited |
CONSTRUCTION OF THE VECTOR OF OBLIGATES ONCOLYTIC HERPES SIMPLEX VIRUSES (OHSV) AND CANCER THERAPY CONSTRUCTIONS
|
JP7039489B2
(ja)
|
2016-05-18 |
2022-03-22 |
ミラティ セラピューティクス, インコーポレイテッド |
Kras g12c阻害剤
|
AU2017290828A1
(en)
|
2016-06-30 |
2019-01-24 |
Virogin Biotech Canada Ltd |
Pseudotyped oncolytic viral delivery of therapeutic polypeptides
|
US10646488B2
(en)
|
2016-07-13 |
2020-05-12 |
Araxes Pharma Llc |
Conjugates of cereblon binding compounds and G12C mutant KRAS, HRAS or NRAS protein modulating compounds and methods of use thereof
|
EP3490583B1
(en)
|
2016-08-01 |
2023-11-29 |
Virogin Biotech Canada Ltd |
Oncolytic herpes simplex virus vectors expressing immune system-stimulatory molecules
|
JP2019529484A
(ja)
|
2016-09-29 |
2019-10-17 |
アラクセス ファーマ エルエルシー |
Kras g12c変異体タンパク質の阻害剤
|
WO2018068017A1
(en)
|
2016-10-07 |
2018-04-12 |
Araxes Pharma Llc |
Heterocyclic compounds as inhibitors of ras and methods of use thereof
|
AU2017379074C9
(en)
|
2016-12-22 |
2023-06-08 |
Amgen Inc. |
Benzisothiazole, isothiazolo[3,4-b]pyridine, quinazoline, phthalazine, pyrido[2,3-d]pyridazine and pyrido[2,3-d]pyrimidine derivatives as KRAS G12C inhibitors for treating lung, pancreatic or colorectal cancer
|
GB201700350D0
(en)
|
2017-01-09 |
2017-02-22 |
Replimune Ltd |
Altered virus
|
US20200385364A1
(en)
|
2017-01-26 |
2020-12-10 |
Araxes Pharma Llc |
Fused n-heterocyclic compounds and methods of use thereof
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
CN110831933A
(zh)
|
2017-05-25 |
2020-02-21 |
亚瑞克西斯制药公司 |
喹唑啉衍生物作为突变kras、hras或nras的调节剂
|
ES2928576T3
(es)
|
2017-09-08 |
2022-11-21 |
Amgen Inc |
Inhibidores de KRAS G12C y métodos de uso de los mismos
|
MX2020011582A
(es)
|
2018-05-04 |
2020-11-24 |
Amgen Inc |
Inhibidores de kras g12c y metodos para su uso.
|
MA52501A
(fr)
*
|
2018-05-04 |
2021-03-10 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MX2020011907A
(es)
|
2018-05-10 |
2021-01-29 |
Amgen Inc |
Inhibidores de kras g12c para el tratamiento de cancer.
|
AU2019278998B2
(en)
|
2018-06-01 |
2023-11-09 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
MX2020012204A
(es)
|
2018-06-11 |
2021-03-31 |
Amgen Inc |
Inhibidores de kras g12c para tratar el cáncer.
|
US11285156B2
(en)
*
|
2018-06-12 |
2022-03-29 |
Amgen Inc. |
Substituted piperazines as KRAS G12C inhibitors
|
CN112313231B
(zh)
|
2018-06-21 |
2023-05-09 |
詹森药业有限公司 |
Oga抑制剂化合物
|
CA3103049A1
(en)
|
2018-06-21 |
2019-12-26 |
Janssen Pharmaceutica Nv |
Oga inhibitor compounds
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
AU2019384118A1
(en)
|
2018-11-19 |
2021-05-27 |
Amgen Inc. |
KRAS G12C inhibitors and methods of using the same
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
CN111484477B
(zh)
|
2019-01-29 |
2022-07-08 |
博瑞生物医药(苏州)股份有限公司 |
一种苯并吡啶酮杂环化合物及其用途
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
AU2020277398A1
(en)
|
2019-05-21 |
2021-12-09 |
Amgen Inc. |
Solid state forms
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
MX2022004656A
(es)
|
2019-10-24 |
2022-05-25 |
Amgen Inc |
Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
|
US20230028414A1
(en)
|
2019-12-16 |
2023-01-26 |
Amgen Inc. |
Dosing regimen of kras g12c inhibitor
|